- Arbutus to Report First Quarter 2024 Financial Results and Provide Corporate Update
- Arbutus Biopharma Announces Claim Construction Ruling in its Ongoing Patent Infringement Lawsuit Against Moderna
- Arbutus to Participate in Two Upcoming Investor Conferences
- Arbutus Reports Fourth Quarter and Year End 2023 Financial Results and Provides Corporate Update
- Arbutus to Report Fourth Quarter and Year End 2023 Financial Results and Provide Corporate Update
- Arbutus Announces 2024 Corporate Objectives and Provides Financial Update
- Arbutus Biopharma and Barinthus Bio Present Preliminary Data from Phase 2a Clinical Trial Combining Imdusiran with VTP-300 at AASLD - The Liver Meeting®
- Arbutus to Present at Jefferies London Healthcare Conference
- Arbutus Reports Third Quarter 2023 Financial Results and Provides Corporate Update
- Arbutus Announces CEO, William Collier, to Retire December 31, 2023
More ▼
Key statistics
On Friday, Arbutus Biopharma Corp (ABUS:NSQ) closed at 2.73, -17.02% below its 52-week high of 3.29, set on Apr 05, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 2.73 |
---|---|
High | 2.78 |
Low | 2.70 |
Bid | 2.71 |
Offer | 2.95 |
Previous close | 2.72 |
Average volume | 983.68k |
---|---|
Shares outstanding | 180.17m |
Free float | 138.11m |
P/E (TTM) | -- |
Market cap | 490.08m USD |
EPS (TTM) | -0.4386 USD |
Data delayed at least 15 minutes, as of Apr 26 2024 21:00 BST.
More ▼